Zobrazeno 1 - 10
of 22 631
pro vyhledávání: ''
Autor:
Xiaoduan Sun, Zhenzhen He, Ruilin Lu, Zhongbing Liu, Sawitree Chiampanichayakul, Songyot Anuchapreeda, Jun Jiang, Singkome Tima, Zhirong Zhong
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Icaritin (ICT), a promising anti-hepatocellular carcinoma (HCC) prenylated flavonoid, is hindered from being applied due to its low water solubility and high lipophilicity in poorly differentiated HCC which is associated with upregulati
Externí odkaz:
https://doaj.org/article/e108c8f065d844dcb87f48b5edafc856
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Clobenpropit is a histamine H3 receptor antagonist and has developed as a potential therapeutic drug due to its ability to inhibit CXCR4, a chemokine receptor involved in autoimmune diseases and cancer pathogenesis. The CXCL12/CXCR4 axis involves sev
Externí odkaz:
https://doaj.org/article/64b4ca7ba62b444288efd366d8652684
Metabolites from traditional Chinese botanical drugs with anti-hepatitis B virus activity - a review
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Hepatitis B virus (HBV)-related liver disease poses a major threat to human health worldwide. Although interferon and nucleoside analogues are commonly administered for treating chronic HBV infection, their use is limited by considerable side effects
Externí odkaz:
https://doaj.org/article/b641c35a0bcd436fac274b16b9575832
Autor:
Xinxia Yang, Dongdong Chen
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundKetamine was developed as an anesthetic. Esketamine is the isolated S-enantiomer of racemic ketamine. They provide new avenues for the treatment of depression, especially treatment-resistant depression. Considering differences in the pharma
Externí odkaz:
https://doaj.org/article/ea141f65b8fd44d6974aa3d439f62d1f
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
ObjectiveBoth camrelizumab plus paclitaxel and carboplatin (CTC) and sintilimab plus gemcitabine and cisplatin or carboplatin (SGP) have been approved by the National Medical Products Administration of China (NMPA) for the first-line treatment of loc
Externí odkaz:
https://doaj.org/article/c620b6394d104f4790ec724f695da51f
Autor:
Yasmin Silva-Santos, Roberta Liberato Pagni, Thais Helena Martins Gamon, Marcela Santiago Pacheco de Azevedo, Mônica Bielavsky, Maria Laura Goussain Darido, Danielle Bruna Leal de Oliveira, Edmarcia Elisa de Souza, Carsten Wrenger, Edson Luiz Durigon, Maria Cecília Rui Luvizotto, Hans Christian Ackerman, Claudio Romero Farias Marinho, Sabrina Epiphanio, Leonardo José Moura Carvalho
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
COVID-19 causes more severe and frequently fatal disease in patients with pre-existing comorbidities such as hypertension and heart disease. SARS-CoV-2 virus enters host cells through the angiotensin-converting enzyme 2 (ACE2), which is fundamental i
Externí odkaz:
https://doaj.org/article/0a80208c429c4258b038df8565cf4881
Autor:
Yanjun Jia, Yanping Wang, Zixia Wang, Zeyu Zhang, Ju Zhang, Jingjing Zhang, Ke Sun, Yongchen Hua, Guolin Chai, Fangdi Hu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Neurological injury, as a major pathogenic mechanism in depression, holds significant importance in the research and development of antidepressant drugs. Hemerocallis citrina Baroni (H. citrina), referred to as “Forgetting Sadness Grass,” has bee
Externí odkaz:
https://doaj.org/article/f0a543bd1f904993b92ad75606ad2a62
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundDelivery systems based on albumin nanoparticles (NPs) have recently garnered substantial interest in anti-tumor drug development. However, systematic bibliometric analyses in this field remain lacking. This study aimed to analyze the curren
Externí odkaz:
https://doaj.org/article/e0adf14dc4564927ab21c43e9faf6976
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundBreast cancer (BC) is one of the most common cancers worldwide. The inevitability of drug resistance to initial anti-HER-2 therapy necessitates the emergence of second-line anti-HER-2 drugs which exhibit a promising outlook. Consequently, i
Externí odkaz:
https://doaj.org/article/762dd4d5e51044a19e4be0c7e8706e3c
Autor:
Uwe Grether, Richard H. Foxton, Sabine Gruener, Claudia Korn, Atsushi Kimbara, Anja Osterwald, Elisabeth Zirwes, Sabine Uhles, Janina Thoele, Nadine Colé, Mark Rogers-Evans, Stephan Röver, Matthias Nettekoven, Rainer E. Martin, Jean-Michel Adam, Jürgen Fingerle, Caterina Bissantz, Wolfgang Guba, André Alker, Anna M. Szczesniak, Ross F. Porter, Tom J. Toguri, Franco Revelant, Agnès Poirier, Camille Perret, Lotte Winther, Antonello Caruso, Filomena Fezza, Mauro Maccarrone, Melanie E. M. Kelly, Sascha Fauser, Christoph Ullmer
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionPreclinical studies suggest that cannabinoid receptor type 2 (CB2R) activation has a therapeutic effect in animal models on chronic inflammation and vascular permeability, which are key pathological features of diabetic retinopathy (DR).
Externí odkaz:
https://doaj.org/article/91d1c3e1c6e44284b2f5d719fd280ff1